Completed PHASE1 INTERVENTIONAL 2-arm NCT00830414

Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women

A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women

Sponsor: Teva Pharmaceuticals USA

Conditions Healthy

Interventions medroxyprogesterone acetate

Updated 4 times since 2017 Last updated: Aug 16, 2024 Started: Apr 30, 2002 Primary completion: Sep 30, 2002 Completion: Sep 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00830414, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Teva Pharmaceuticals USA, it has been updated 4 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Pharmaceuticals USA

Data source: Teva Pharmaceuticals USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Neu-Ulm, Germany